The Competition and Markets Authority (CMA) has released a sweeping set of proposals to reform the United Kingdom’s £6.3 billion veterinary services market, recommending 21 legally binding measures designed to lower pet care costs, enhance price transparency, and strengthen regulatory oversight of corporate vet groups. In its provisional decision, the regulator cited structural market issues that have enabled opaque pricing, excessive prescription charges, and weakened consumer choice—particularly in a sector where pet ownership has soared and chains now dominate local practice networks.
The CMA concluded that the current regulatory framework is no longer fit for purpose and fails to protect pet owners from overspending or unfair commercial practices. The investigation, launched in 2023 following a record 56,000 responses from pet owners and professionals, found widespread confusion around vet pricing, limited access to comparative data, and growing concern that corporate consolidation is reducing competition and inflating costs.
What structural issues did the CMA identify in the UK veterinary sector and why is reform now considered urgent?
Between 2016 and 2023, average vet prices across the UK rose by 63%, significantly outpacing inflation. The CMA’s investigation uncovered that many pet owners remain unaware of how much common treatments or services should cost, and often do not know whether their local vet clinic is independently owned or part of a large corporate group. Moreover, many customers receive no written estimate for treatments that may run into hundreds—or even thousands—of pounds.
The regulator found that pet owners are frequently overpaying for medicines prescribed by vet clinics, often being charged double the amount they could pay through online pharmacies. A key finding revealed that pet owners pay 16.6% more on average at clinics owned by large veterinary groups compared to independents. In at least three large groups, prices increased more sharply at acquired clinics than those still operating independently.
These systemic pricing disparities, paired with a lack of accessible comparison tools, have led the CMA to provisionally conclude that there is a serious shortfall in effective competition across the UK’s veterinary services market. For a substantial portion of the sector, profits are deemed significantly higher than what would be expected in a functioning competitive environment.
What reforms has the CMA proposed to empower pet owners and reduce overcharging for treatments and medicines?
To address these market failures, the CMA’s provisional decision outlines a 21-point package of reforms designed to restore competitive discipline, reduce information asymmetry, and modernize the UK’s outdated veterinary regulatory system.
Key proposals include mandating all veterinary businesses to publish comprehensive price lists for standard treatments and services, clearly disclose ownership structures, and ensure policies allow clinical decisions to be made in the best interest of pets and their owners—free from commercial pressure. Where treatments are expected to exceed £500, practices would be required to provide written cost estimates upfront.
Another major measure involves capping the cost of providing a written prescription at £16. In addition, veterinary clinics would be obliged to proactively inform pet owners of the potential savings from buying medication online. For frequently prescribed medications, clinics would need to automatically issue written prescriptions unless owners opt out.
To further support transparency, the CMA has recommended enhancements to the Royal College of Veterinary Surgeons’ “Find a Vet” platform. The upgraded site would include searchable pricing data from vet practices across the country, offering consumers a way to compare services and costs when choosing a provider or relocating.
Pet cremation services, pet care plans, and bundled service offerings will also be subjected to new transparency rules. The CMA proposes mandatory itemized breakdowns for pet care plans and cremation charges, ensuring pet owners can make fully informed decisions during emotionally vulnerable periods.
Why is regulation of corporate vet groups a central focus of the CMA’s recommendations?
One of the most significant regulatory gaps identified by the CMA is the lack of statutory oversight over veterinary businesses, even though most UK vet practices are now owned by large chains such as CVS Group, Linnaeus (Mars Inc.), VetPartners, Medivet, Pets at Home, and IVC Evidensia.
The existing regulatory structure—anchored in the 1966 Veterinary Surgeons Act—governs only individual professionals such as vets and nurses, but provides no legal framework for regulating the business operations of corporate chains. This mismatch has become increasingly problematic as corporate ownership has scaled rapidly in recent years, leaving pet owners exposed to pricing policies that prioritize profitability over patient welfare.
The CMA has urged the UK government to prioritize legislative reform by introducing a new Veterinary Surgeons Act that would enable statutory oversight of veterinary businesses. It recommends expanding the regulatory remit of the Royal College of Veterinary Surgeons to cover commercial practices, set operational standards, and enforce penalties or corrective measures where necessary.
How are institutional stakeholders and vet groups responding to the CMA’s market findings and proposed measures?
Institutional sentiment appears cautiously supportive of the CMA’s approach, with analysts viewing the proposals as strong on consumer protection but balanced enough to avoid overly punitive regulation for vet groups. Crucially, the CMA has not proposed any forced breakups of large chains or hard price caps on services beyond prescriptions.
The British Veterinary Association (BVA) has expressed measured support for the push toward greater transparency and modernized regulation, but cautioned against reforms that may oversimplify the complexity of care provision. The BVA noted that rigid price listing requirements might undermine flexibility and even discourage personalized care decisions that reflect animal welfare needs.
CVS Group, one of the six large veterinary businesses named in the CMA probe, stated that while it does not agree with all findings, it is open to collaboration and will consider proactive adjustments. Investors interpreted the CMA’s position as a sign that systemic regulation—rather than aggressive market intervention—will shape the next phase of reform. Shares of CVS Group and Pets at Home rose following the announcement, reflecting relief that more disruptive remedies such as divestment or revenue-linked caps were not pursued.
What is the timeline for implementation and what steps will follow the consultation phase?
The CMA will now open a consultation phase, accepting responses from industry players, consumers, and stakeholders until Wednesday, 12 November 2025. A final decision is expected by March 2026. If the proposed remedies are adopted, they will be implemented via a legally binding CMA Order.
While some of the reforms could come into force before the end of 2026, smaller vet businesses may be granted additional transition time. However, the CMA emphasized that all veterinary businesses—regardless of size—will be required to comply eventually. It has also encouraged vet businesses to voluntarily begin implementing measures such as price disclosures and prescription flexibility ahead of the regulatory deadline.
The regulator acknowledged that implementation may involve some administrative costs for businesses but maintained that the long-term consumer benefits would substantially outweigh these. It also reiterated its concern over reports of client abuse directed at vet staff and clarified that the proposals target structural business practices, not individual veterinary professionals.
What could this reform package mean for pet owners, veterinary practices, and future market dynamics?
For pet owners, the CMA’s proposed reforms promise a dramatically more transparent and consumer-friendly environment. Access to upfront pricing, online medication alternatives, itemized billing, and clearer ownership disclosure could reduce overspending, especially for those unaware of cheaper treatment paths.
For independent veterinary practices, the reforms could level the competitive playing field by forcing larger chains to compete more directly on value and service. For corporate veterinary businesses, the package marks a turning point that may require significant internal adjustments in pricing, branding, client communication, and regulatory compliance strategy.
If successful, the CMA’s measures could spark a wider shift in how veterinary services are delivered, moving the sector closer to the standards of transparency and accountability expected in other regulated professional services industries such as dentistry, pharmacy, and private healthcare.
In the short term, investor sentiment may remain positive as regulatory clarity reduces uncertainty and supports a more stable operating environment. But over the medium term, compliance costs, pricing pressure, and operational scrutiny could challenge margins and incentivize innovation in customer acquisition, pricing technology, and bundled care strategies.
The outcome of the public consultation will be critical in shaping the final form of these rules. Until then, both vet groups and consumers await clarity on whether 2026 will mark a watershed moment for pet care in the UK—or merely the start of a longer regulatory journey.
Discover more from Business-News-Today.com
Subscribe to get the latest posts sent to your email.
